Central nervous system (CNS) research is making breakthroughs with innovative therapies and next-generation technologies. Researchers are now able to use human tissue to identify relevant novel drug targets and biomarkers for a broad range of CNS diseases including schizophrenia, Alzheimer’s disease and Parkinson’s disease. As our understanding of the brain…
List view / Grid view
The researchers found restoring mitochondrial homeostasis in the diseased neurons could protect the optic nerve cells from being damaged from glaucoma.
The new ‘hybrid’ hydrogel allowed researchers to safely deliver stem cells to the site of a brain injury in mice.
Drug Target Review’s Ria Kakkad recently travelled to Barcelona to attend PEGS Europe’s Protein and Antibody Engineering Summit. In this article, she shares her highlights from the event.
The study, involving mice, found that the neurotransmitter can act as a break to dopamine.
Researchers have developed a nanobody that can penetrate the tough exterior of brain cells and untangle misshapen proteins that lead to Parkinson’s disease.
NRG Therapeutics to develop small molecule disease-modifying medicines for debilitating chronic neurodegenerative disorders
NRG is developing a pipeline of brain-penetrant small molecule inhibitors of the mitochondrial permeability transition pore (mPTP) with potential as first-in-class treatments for Parkinson's disease and motor neuron disease.
Ultra-powerful 7T MRI scanners could be used to help identify those patients with Parkinson’s disease and similar conditions most likely to benefit from new treatments for previously untreatable symptoms.
In a new study, researchers describe a process for converting non-neuronal cells into functioning neurons able to restore capacities undermined by Parkinson’s destruction of dopaminergic cells.
Neuroscientists have designed brain organoids to contain both mature neurons and astrocytic glial cells in relative proportions like the human brain.
A study has shown how Parkinson’s disease may be driven by cell stress-related biochemical events that disrupt a key cellular clean-up system.
Research from the University of Copenhagen reveals how Deep Brain Stimulation treatment of walking problems in Parkinson’s disease could be optimised by targeting specific neurons in the brainstem.
Dr Greg Neely, University of Sydney, explains how he and his team used pooled whole genome CRISPR activation screening to identify LRRC15 as a SARS-CoV-2 spike-interacting protein.
A new platform, named Virtual Synthon Hierarchical Enumeration Screening, has been developed by researchers to efficiently discover drugs.
Dr Antal Szalay, CEO and Founder of Ultimate Medicine, explores how the analysis of omics data, especially metabolomics and proteomics, can provide researchers with vital insight that can inform the development of drugs for conditions associated with age.